DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Janney Capital Upgrades DepoMed Inc (DEPO) to Buy
May 12, 2015 12:23 PM EDTJanney Capital upgraded DepoMed Inc (NASDAQ: DEPO) from Neutral to Buy with a price target of $25.50.
Analyst Chiara Russon commented, "With DEPO opening down ~18.5% this morning, this puts our $25.50 FV squarely in the 20% upside, enough to give the name a Buy rating.... More
DepoMed (DEPO) Misses Q1 EPS by 14c; Guides FY15 Sales Above Views
May 11, 2015 4:15 PM EDTDepoMed (NASDAQ: DEPO) reported Q1 EPS of ($0.13), $0.14 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $31.7 million versus the consensus estimate of $33.8 million.
DepoMed sees FY2015 revenue of $310-335 million, versus the consensus of $305.02 million.
For earnings history and earnings-related data on DepoMed (DEPO) click here.
... More